Brief: Xuanzhu Biopharmaceutical Says Approved To Initiate Phase Iii Trial Of Anaprazole Sodium
15/04/2026 02:48
April 15 (Reuters) - Xuanzhu Biopharmaceutical 2575.HK: APPROVED TO INITIATE PHASE III TRIAL OF ANAPRAZOLE SODIUM FOR HELICOBACTER PYLORI ERADICATION Further company coverage: 2575.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xuanzhu Biopharmaceutical
See all newsBrief: Xuanzhu Biopharmaceutical Announces Commercial Cooperation With Innobic For Birecociclib
Xuanzhu Biopharmaceutical climbs to three-week high on approval for drug clinical trial
Brief: Xuanzhu Biopharmaceutical Says Approved To Initiate Phase Iii Trial Of Anaprazole Sodium
China's Xuanzhu set for best day in 6 months on drug deal with Boston Oncology
Brief: Xuanzhu Biopharmaceutical Enters Licensing Agreement With Boston Oncology